Girija Balasaheb Bhavar
Research Subjects
Girija Balasaheb Bhavar has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Kiran Balasaheb Aher
Department of Pharmaceutical Quality Assurance SVKM NMIMS Global University, Dhule, Maharashtra, India
5 shared publications - Mohammad Habeeb
Department of Pharmaceutics, Crescent School of Pharmacy, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai, Tamilnadu, India
4 shared publications - Hariharan Thirumalai Vengateswaran
Department of Pharmaceutics, Crescent School of Pharmacy, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai, 600048, Tamil Nadu, India
3 shared publications - Huay Woon You
Pusat PERMATA@Pintar Negara, Universiti Kebangsaan Malaysia
3 shared publications - Aditi Kulkarni
Department of Pharmacognosy, Smt. Kashibai Navale College of Pharmacy, Kondhwa (Bk), Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, India
1 shared publication Huay Woon You
1 shared publication
Latest Publications
- Open Access
- 30 August 2024
- Published by International Academic Publishing House in INTERNATIONAL JOURNAL OF EXPERIMENTAL RESEARCH AND REVIEW
- Vol. 42, 241-248
Development and Validation of an ICH-Compliant Optimized RP-HPLC Method for Quantitative Analysis of Favipiravir
Favipiravir (FAV) has emerged as a promising antiviral agent. It is particularly effective against influenza and other RNA virus infections. The aim and objective of the present study was developing and optimizing chromatographic conditions for faster analysis of FAV and demonstrating its applicability for tablet assay. The chromatographic separation was obtained using mobile phase with 90:10 % v/v ratio of ammonium acetate buffer (pH 4.5) and methanol on a Waters C18 column (250 x 4.6 mm, 5 µ). A flow rate of 1.4 mL/min was optimized. Chromatographic detection was perform at a wavelength of 323 nm. The FAV retention time was 6.46 min, indicating the efficiency and speed of the method. The developed method was rigorously validated according to ICH guidelines. A strong linear correlation (r2 = 0.9995) was established in the 5–60 ?g/mL range, indicating adequacy for quantitative analysis. The method demonstrated high accuracy, with FAV recovery ranging from 98.77 % to 100.89 %. The % RSD results of less than 2% for intermediate precision and repeatability showed that the method exhibited high precision. The developed HPLC method reduces the Rt. Notably, this method complies with regulatory standards, establishing it as a valuable tool for quality assurance, pharmacological evaluation, and clinical monitoring of FAV. Thus, this validated RP-HPLC method provides a robust and sensitive method for routine FAV quantification, with high accuracy, precision, and compliance results, supporting its potential use in the clinical pharmaceutical industry.
- 30 August 2024
- Published by International Academic Publishing House in INTERNATIONAL JOURNAL OF EXPERIMENTAL RESEARCH AND REVIEW
- Vol. 42, 241-248
Open AccessDevelopment and Validation of an ICH-Compliant Optimized RP-HPLC Method for Quantitative Analysis of Favipiravir
Favipiravir (FAV) has emerged as a promising antiviral agent. It is particularly effective against influenza and other RNA virus infections. The aim and objective of the present study was developing and optimizing chromatographic conditions for faster analysis of FAV and demonstrating its applicability for tablet assay. The chromatographic separation was obtained using mobile phase with 90:10 % v/v ratio of ammonium acetate buffer (pH 4.5) and methanol on a Waters C18 column (250 x 4.6 mm, 5 µ). A flow rate of 1.4 mL/min was optimized. Chromatographic detection was perform at a wavelength of 323 nm. The FAV retention time was 6.46 min, indicating the efficiency and speed of the method. The developed method was rigorously validated according to ICH guidelines. A strong linear correlation (r2 = 0.9995) was established in the 5–60 ?g/mL range, indicating adequacy for quantitative analysis. The method demonstrated high accuracy, with FAV recovery ranging from 98.77 % to 100.89 %. The % RSD results of less than 2% for intermediate precision and repeatability showed that the method exhibited high precision. The developed HPLC method reduces the Rt. Notably, this method complies with regulatory standards, establishing it as a valuable tool for quality assurance, pharmacological evaluation, and clinical monitoring of FAV. Thus, this validated RP-HPLC method provides a robust and sensitive method for routine FAV quantification, with high accuracy, precision, and compliance results, supporting its potential use in the clinical pharmaceutical industry.
- 8 January 2024
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 12 (7) , 1677-1705
Nanomedicine facilitated cell signaling blockade: difficulties and strategies to overcome glioblastoma
Nanocarriers loaded with anticancer agents strategically intervene to block cell signaling pathways in glioblastoma.
- 8 January 2024
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 12 (7) , 1677-1705
Nanomedicine facilitated cell signaling blockade: difficulties and strategies to overcome glioblastoma
Nanocarriers loaded with anticancer agents strategically intervene to block cell signaling pathways in glioblastoma.
- Open Access
- 30 August 2023
- Published by International Academic Publishing House in INTERNATIONAL JOURNAL OF EXPERIMENTAL RESEARCH AND REVIEW
- Vol. 32, 387-397
Comparative analysis of analytical method development and its validation for the simultaneous estimation of Bilastine and Montelukast Sodium in bulk and its tablet formulation by planar chromatography
The development and validation of analytical methods are crucial in guaranteeing the precision, dependability, and excellence of pharmaceutical analysis. This research investigates the field of pharmaceutical chemistry by doing a comparative examination of analytical techniques for the simultaneous determination of Bilastine and Montelukast Sodium in both bulk and tablet forms. The selected method for this analysis is planar chromatography. The simplicity, specificity, precision, and accuracy of a high-performance liquid chromatography (HPTLC) approach were investigated for their use in the simultaneous estimation of the antihistaminic combination medication Bilastine and Montelukast Sodium in bulk and its pharmaceutical dose for the treatment of allergic rhinitis. Densitometric readings were taken at 254 nm after separating substances using ethyl acetate, toluene, methanol, and ammonia (7:0.5:1.5:0.5v/v/v/v) as mobile phase and precoated aluminium silica gel plates (60F254) as stationary phase. Bilastine and montelukast Sodium have Rf values 0.2 (Bilastine) & 0.4 (Montelukast Sodium), which is considered an acceptable resolution. The International Conference on Harmonization's (ICH) requirements validated the processes for accuracy, linearity, precision, robustness, and system adaptability. Bilastine and Montelukast Sodium concentrations were determined without any disruption from the excipients. Both Bilastine and Montelukast Sodium were effectively quantified using the suggested method, which bodes well for its utility in enhancing quality assurance.
- 30 August 2023
- Published by International Academic Publishing House in INTERNATIONAL JOURNAL OF EXPERIMENTAL RESEARCH AND REVIEW
- Vol. 32, 387-397
Open AccessComparative analysis of analytical method development and its validation for the simultaneous estimation of Bilastine and Montelukast Sodium in bulk and its tablet formulation by planar chromatography
The development and validation of analytical methods are crucial in guaranteeing the precision, dependability, and excellence of pharmaceutical analysis. This research investigates the field of pharmaceutical chemistry by doing a comparative examination of analytical techniques for the simultaneous determination of Bilastine and Montelukast Sodium in both bulk and tablet forms. The selected method for this analysis is planar chromatography. The simplicity, specificity, precision, and accuracy of a high-performance liquid chromatography (HPTLC) approach were investigated for their use in the simultaneous estimation of the antihistaminic combination medication Bilastine and Montelukast Sodium in bulk and its pharmaceutical dose for the treatment of allergic rhinitis. Densitometric readings were taken at 254 nm after separating substances using ethyl acetate, toluene, methanol, and ammonia (7:0.5:1.5:0.5v/v/v/v) as mobile phase and precoated aluminium silica gel plates (60F254) as stationary phase. Bilastine and montelukast Sodium have Rf values 0.2 (Bilastine) & 0.4 (Montelukast Sodium), which is considered an acceptable resolution. The International Conference on Harmonization's (ICH) requirements validated the processes for accuracy, linearity, precision, robustness, and system adaptability. Bilastine and Montelukast Sodium concentrations were determined without any disruption from the excipients. Both Bilastine and Montelukast Sodium were effectively quantified using the suggested method, which bodes well for its utility in enhancing quality assurance.
- 20 April 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 84
Strategies of nanomedicine for targeting the signaling pathways of Colorectal cancer
- 20 April 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 84
Strategies of nanomedicine for targeting the signaling pathways of Colorectal cancer
- Open Access
- 1 January 2016
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 84 (2) , 305-320
High-Performance Liquid Chromatographic and High-Performance Thin-Layer Chromatographic Method for Quantitative Estimation of Dolutegravir Sodium in Bulk Drug and Pharmaceutical Dosage Form
Simple, sensitive, precise, and specific high-performance liquid chromategraphic (HPLC) and high-performance thin-layer chromatographic (HPTLC) methods for the determination of dolutegravir sodium in bulk drug and pharmaceutical dosage form were developed and validated. In the HPLC method, analysis of the drug was carried out on the ODS C18 column (150 × 4.6 mm, 5 μm particle size) using a mixture of acetonitrile: water (pH 7.5) in the ratio of 80:20 v/v as the mobile phase at the flow rate 1 mL/min at 260 nm. This method was found to be linear in the concentration range of 5-35 μg/mL. The peak for dolutegravir sodium was observed at 3.0 ± 0.1 minutes. In the HPTLC method, analysis was performed on aluminum-backed plates pre-coated with silica gel G60 F254 using methanol: chloroform: formic acid in the proportion of 8:2:0.5 v/v/v as the mobile phase. This solvent system was found to give compact spots for dolutegravir sodium with the Rf value 0.77 ± 0.01. Densitometric analysis of dolutegravir sodium was carried out in the absorbance mode at 265 nm. Linear regression analysis showed good linearity with respect to peak area in the concentration range of 200-900 ng/spot. The methods were validated for precision, limit of detection (LOD), limit of quantitation (LOQ), accuracy, and specificity. Statistical analysis showed that both of the methods are repeatable and specific for the estimation of the said drug. The methods can be used for routine quality control analysis of dolutegravir sodium.
- 1 January 2016
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 84 (2) , 305-320
Open AccessHigh-Performance Liquid Chromatographic and High-Performance Thin-Layer Chromatographic Method for Quantitative Estimation of Dolutegravir Sodium in Bulk Drug and Pharmaceutical Dosage Form
Simple, sensitive, precise, and specific high-performance liquid chromategraphic (HPLC) and high-performance thin-layer chromatographic (HPTLC) methods for the determination of dolutegravir sodium in bulk drug and pharmaceutical dosage form were developed and validated. In the HPLC method, analysis of the drug was carried out on the ODS C18 column (150 × 4.6 mm, 5 μm particle size) using a mixture of acetonitrile: water (pH 7.5) in the ratio of 80:20 v/v as the mobile phase at the flow rate 1 mL/min at 260 nm. This method was found to be linear in the concentration range of 5-35 μg/mL. The peak for dolutegravir sodium was observed at 3.0 ± 0.1 minutes. In the HPTLC method, analysis was performed on aluminum-backed plates pre-coated with silica gel G60 F254 using methanol: chloroform: formic acid in the proportion of 8:2:0.5 v/v/v as the mobile phase. This solvent system was found to give compact spots for dolutegravir sodium with the Rf value 0.77 ± 0.01. Densitometric analysis of dolutegravir sodium was carried out in the absorbance mode at 265 nm. Linear regression analysis showed good linearity with respect to peak area in the concentration range of 200-900 ng/spot. The methods were validated for precision, limit of detection (LOD), limit of quantitation (LOQ), accuracy, and specificity. Statistical analysis showed that both of the methods are repeatable and specific for the estimation of the said drug. The methods can be used for routine quality control analysis of dolutegravir sodium.